By Michael Dabaie

 

Orchard Therapeutics said it is in license agreements with GlaxoSmithKline PLC.

The agreements are for use of Glaxo's lentiviral stable cell line technology for Orchard's investigational hematopoietic stem cell gene therapies for Wiskott Aldrich syndrome and transfusion-dependent beta thalassemia.

Orchard said it plans to submit a biologics license application and marketing authorization application for OTL-103 for the Wiskott Aldrich syndrome in the U.S. and EU, respectively, in 2021.

Orchard said it doesn't expect the terms of the license to have a material impact on Orchard's financial position or near-term cash needs.

Orchard ADRs were up 8% to $5.54 premarket.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

July 15, 2020 07:45 ET (11:45 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Gsk
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Gsk